Infection in Solid Organ Transplant Recipients clinical trials at UCLA

1 in progress, 0 open to eligible people

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
Sorry, in progress, not accepting new patients
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
Los Angeles, California

Our lead scientists for Infection in Solid Organ Transplant Recipients research studies include Jaime Deville.

Last updated: March 2023

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)